arrow
M

Marcello Tiseo

university of parma
H指数:66
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
Response to Letter Re: Real-World Outcomes of Immunotherapy Discontinuation at Two Years in Advanced Non-Small Cell Lung Cancer: final results of the ISTOP study.

回复函:关于晚期非小细胞肺癌免疫疗法停药两年后的真实世界结局:ISTOP研究的最终结果。

2026-05-020
PRE
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

在晚期非小细胞肺癌中免疫疗法停药两年的真实世界结局:I-STOP研究的最终结果

2026-02-190
PRE
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients

患者报告结局的不良事件常用术语标准(PRO-CTCAE)在意大利肺癌患者中的有效性和敏感性

2026-02-080
OAAI
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

EGFR突变晚期非小细胞肺癌患者在接受一线奥希替尼治疗后,接受卡铂联合培美曲塞二线治疗的实际疗效:一项国际多中心队列研究

2025-10-160
PRE
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

赛沃替尼联合奥希替尼治疗表皮生长因子受体(EGFR)突变型晚期非小细胞肺癌,该患者伴有MET过表达和/或扩增,且在奥希替尼治疗进展后:SAVANNAH II期研究的主要结果

2025-06-020
OAAI
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对晚期非小细胞肺癌(NSCLC)及体力状态较差患者的态度与生存结局的前瞻性研究:PICASO(GOIRC-04-2020)。

2025-06-010
PRE
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study

卡博平、依托泊苷、阿替利珠单抗和贝伐珠单抗在广泛期小细胞肺癌患者的一线治疗中:GOIRC-01-2019 CeLEBrATE 研究

2025-05-070
OA
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review

解开胆固醇和免疫系统在癌症之间的联系: 从生物学机制的见解到临床证据。叙述性评论

2025-05-010
PRE
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)

奥德沙班相关不良事件对接受抗肿瘤治疗并发静脉血栓栓塞的癌症患者的影响:EDOI研究(GOIRC-05-2018)IV期研究结果

2025-03-010
OAAI
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study
2024-10-220
OA
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines

靶向葡萄糖饥饿诱导的代谢适应性反应抑制奥希替尼耐药非小细胞肺癌 (NSCLC) 细胞系的细胞增殖并增加细胞死亡

2024-10-011
OAAI
Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients

动态血液免疫炎症和放射组学分析以解码NSCLC患者对免疫疗法获得性耐药的不同模式

2024-09-010
PRE
Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2024-09-010
PRE
Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study

舒沃哲在既往接受铂类治疗的、携带EGFR外显子20插入突变的NSCLC患者中的疗效与安全性:跨国WU-KONG1B关键性研究的主要分析

2024-09-011
PRE